Cargando…

A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease

PURPOSE: NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. METHODS: SEECASE was a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Tauber, Joseph, Wirta, David L., Sall, Kenneth, Majmudar, Parag A., Willen, Daniela, Krösser, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cornea 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330824/
https://www.ncbi.nlm.nih.gov/pubmed/33369937
http://dx.doi.org/10.1097/ICO.0000000000002622
_version_ 1783732801271496704
author Tauber, Joseph
Wirta, David L.
Sall, Kenneth
Majmudar, Parag A.
Willen, Daniela
Krösser, Sonja
author_facet Tauber, Joseph
Wirta, David L.
Sall, Kenneth
Majmudar, Parag A.
Willen, Daniela
Krösser, Sonja
author_sort Tauber, Joseph
collection PubMed
description PURPOSE: NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. METHODS: SEECASE was a prospective, multicenter, randomized, double-masked, saline-controlled clinical study. A total of 336 DED patients [tear film breakup time ≤5 seconds, abnormal meibum secretion, total corneal fluorescein staining (tCFS) score of 4 ≤ X ≤ 11 (National Eye Institute scale), Schirmer of ≥5 mm] were randomized in a 2:2:1:1 manner to NOV03 4 times daily (QID), NOV03 twice daily (BID), saline BID, and saline QID, respectively. The primary efficacy endpoint was tCFS staining at 8 weeks for both regimens. Secondary endpoints included visual analog scales and the Ocular Surface Disease Index questionnaire for symptom assessment. RESULTS: The study met its primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID (P < 0.001 and P = 0.009, respectively). NOV03 also showed pronounced improvement in various symptoms. For the Eye Dryness Score, changes from baseline were statistically significant compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002 (BID)]. Benefits on tCFS and symptoms started at 2 weeks after start of treatment and were maintained over the study duration. The effects were dosing schedule dependent. NOV03 was well tolerated with instillation site reactions below 3% in both treatment regimes. CONCLUSIONS: The SEECASE study demonstrated that NOV03 improves signs and symptoms in patients with highly symptomatic evaporative dry eye disease.
format Online
Article
Text
id pubmed-8330824
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cornea
record_format MEDLINE/PubMed
spelling pubmed-83308242021-08-10 A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease Tauber, Joseph Wirta, David L. Sall, Kenneth Majmudar, Parag A. Willen, Daniela Krösser, Sonja Cornea Clinical Science PURPOSE: NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. METHODS: SEECASE was a prospective, multicenter, randomized, double-masked, saline-controlled clinical study. A total of 336 DED patients [tear film breakup time ≤5 seconds, abnormal meibum secretion, total corneal fluorescein staining (tCFS) score of 4 ≤ X ≤ 11 (National Eye Institute scale), Schirmer of ≥5 mm] were randomized in a 2:2:1:1 manner to NOV03 4 times daily (QID), NOV03 twice daily (BID), saline BID, and saline QID, respectively. The primary efficacy endpoint was tCFS staining at 8 weeks for both regimens. Secondary endpoints included visual analog scales and the Ocular Surface Disease Index questionnaire for symptom assessment. RESULTS: The study met its primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID (P < 0.001 and P = 0.009, respectively). NOV03 also showed pronounced improvement in various symptoms. For the Eye Dryness Score, changes from baseline were statistically significant compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002 (BID)]. Benefits on tCFS and symptoms started at 2 weeks after start of treatment and were maintained over the study duration. The effects were dosing schedule dependent. NOV03 was well tolerated with instillation site reactions below 3% in both treatment regimes. CONCLUSIONS: The SEECASE study demonstrated that NOV03 improves signs and symptoms in patients with highly symptomatic evaporative dry eye disease. Cornea 2021-09 2020-12-22 /pmc/articles/PMC8330824/ /pubmed/33369937 http://dx.doi.org/10.1097/ICO.0000000000002622 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Science
Tauber, Joseph
Wirta, David L.
Sall, Kenneth
Majmudar, Parag A.
Willen, Daniela
Krösser, Sonja
A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title_full A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title_fullStr A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title_full_unstemmed A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title_short A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
title_sort randomized clinical study (seecase) to assess efficacy, safety, and tolerability of nov03 for treatment of dry eye disease
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330824/
https://www.ncbi.nlm.nih.gov/pubmed/33369937
http://dx.doi.org/10.1097/ICO.0000000000002622
work_keys_str_mv AT tauberjoseph arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT wirtadavidl arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT sallkenneth arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT majmudarparaga arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT willendaniela arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT krossersonja arandomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT tauberjoseph randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT wirtadavidl randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT sallkenneth randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT majmudarparaga randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT willendaniela randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease
AT krossersonja randomizedclinicalstudyseecasetoassessefficacysafetyandtolerabilityofnov03fortreatmentofdryeyedisease